Chimeric antigen receptor (CAR) T cells have emerged as a potent therapeutic approach for
patients with certain haematological cancers, with multiple CAR T cell products currently …

Background More than 90% of the adult population globally is chronically infected by the
Epstein–Barr virus (EBV). It is well established that EBV is associated with a number of …

Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma
worldwide, representing approximately 30–40% of all cases in different geographic regions …

New therapies are needed for patients with Hodgkin or non-Hodgkin lymphomas that are
resistant to standard therapies. Indeed, unresponsiveness to standard chemotherapy and …

Purpose T cells genetically modified to express chimeric antigen receptors (CARs) targeting
CD19 (CAR-19) have potent activity against acute lymphoblastic leukemia, but fewer results …

Purpose T cells can be genetically modified to express an anti-CD19 chimeric antigen
receptor (CAR). We assessed the safety and efficacy of administering autologous anti-CD19 …

T cells expressing anti-CD19 chimeric antigen receptors (CARs) can induce complete
remissions (CRs) of diffuse large B cell lymphoma (DLBCL). The long-term durability of …

The MYC transcription factor, encoded by the c‐MYC proto‐oncogene, is activated by
growth‐promoting signals, and is a key regulator of biosynthetic and metabolic pathways …

The dosage of soluble programmed cell death ligand 1 (sPD-L1) protein in the blood of
adults with cancer has never been performed in a prospective patient cohort. We evaluated …

Background Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an oncofetal protein
present on many cancers. Zilovertamab vedotin (ZV) is an antibody–drug conjugate …